Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 544

1.

Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.

Coburn JW, Maung HM, Elangovan L, Germain MJ, Lindberg JS, Sprague SM, Williams ME, Bishop CW.

Am J Kidney Dis. 2004 May;43(5):877-90.

PMID:
15112179
2.

Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism.

Frazão JM, Elangovan L, Maung HM, Chesney RW, Acchiardo SR, Bower JD, Kelley BJ, Rodriguez HJ, Norris KC, Robertson JA, Levine BS, Goodman WG, Gentile D, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW.

Am J Kidney Dis. 2000 Sep;36(3):550-61.

PMID:
10977787
3.

19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.

Martin KJ, González EA, Gellens M, Hamm LL, Abboud H, Lindberg J.

J Am Soc Nephrol. 1998 Aug;9(8):1427-32.

4.

Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2.

Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, Arruda J, Lau A, Slatopolsky E.

Am J Kidney Dis. 1998 Oct;32(2 Suppl 2):S48-54.

PMID:
9808143
5.

Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.

Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM.

Am J Kidney Dis. 2006 Feb;47(2):263-76.

PMID:
16431255
6.

Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.

Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM.

Am J Nephrol. 2008;28(1):97-106. Epub 2007 Oct 3.

PMID:
17914251
8.

Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison.

Maung HM, Elangovan L, Frazão JM, Bower JD, Kelley BJ, Acchiardo SR, Rodriguez HJ, Norris KC, Sigala JF, Rutkowski M, Robertson JA, Goodman WG, Levine BS, Chesney RW, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW.

Am J Kidney Dis. 2001 Mar;37(3):532-43.

PMID:
11228177
9.

Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.

Greenbaum LA, Benador N, Goldstein SL, Paredes A, Melnick JZ, Mattingly S, Amdahl M, Williams LA, Salusky IB.

Am J Kidney Dis. 2007 Jun;49(6):814-23.

PMID:
17533024
10.

Real-world doxercalciferol treatment in SHPT CKD stage 3 and 4: an analysis of change in iPTH and accordance to KDOQI recommendations.

Kumar N, Lindberg J, David K, Morris J, Menoyo J.

Am J Nephrol. 2009;29(2):71-8. doi: 10.1159/000151275. Epub 2008 Aug 8.

PMID:
18689981
11.

A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.

Lindberg J, Martin KJ, González EA, Acchiardo SR, Valdin JR, Soltanek C.

Clin Nephrol. 2001 Oct;56(4):315-23.

PMID:
11680662
12.

Vitamin D analogues for the management of secondary hyperparathyroidism.

Martin KJ, González EA.

Am J Kidney Dis. 2001 Nov;38(5 Suppl 5):S34-40. Review.

PMID:
11689385
13.

The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD.

Kooienga L, Fried L, Scragg R, Kendrick J, Smits G, Chonchol M.

Am J Kidney Dis. 2009 Mar;53(3):408-16. doi: 10.1053/j.ajkd.2008.09.020. Epub 2009 Jan 29.

PMID:
19185400
14.

Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis.

Charytan C, Coburn JW, Chonchol M, Herman J, Lien YH, Liu W, Klassen PS, McCary LC, Pichette V.

Am J Kidney Dis. 2005 Jul;46(1):58-67.

PMID:
15983958
15.

Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2.

Martin KJ, González EA, Gellens ME, Hamm LL, Abboud H, Lindberg J.

Am J Kidney Dis. 1998 Oct;32(2 Suppl 2):S61-6.

PMID:
9808145
16.

Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study.

Martin KJ, González E, Lindberg JS, Taccetta C, Amdahl M, Malhotra K, Llach F.

Am J Kidney Dis. 2001 Nov;38(5 Suppl 5):S57-63.

PMID:
11689389
17.

Doxercalciferol treatment of secondary hyperparathyroidism.

Dennis VC, Albertson GL.

Ann Pharmacother. 2006 Nov;40(11):1955-65. Epub 2006 Oct 24. Review.

PMID:
17062838
19.

Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial.

Ito H, Ogata H, Yamamoto M, Takahashi K, Shishido K, Takahashi J, Taguchi S, Kinugasa E.

Clin Nephrol. 2009 Jun;71(6):660-8.

PMID:
19473635
20.

Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients.

Joist HE, Ahya SN, Giles K, Norwood K, Slatopolsky E, Coyne DW.

Clin Nephrol. 2006 May;65(5):335-41.

PMID:
16724654
Items per page

Supplemental Content

Write to the Help Desk